Curis (CRIS) Competitors $2.41 +0.02 (+0.84%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$2.38 -0.03 (-1.24%) As of 03/27/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. LXRX, RGLS, DOMH, FBIO, AGEN, BOLT, SABS, MTEM, AMGN, and GILDShould you be buying Curis stock or one of its competitors? The main competitors of Curis include Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), Dominari (DOMH), Fortress Biotech (FBIO), Agenus (AGEN), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), Amgen (AMGN), and Gilead Sciences (GILD). These companies are all part of the "biotechnology" industry. Curis vs. Lexicon Pharmaceuticals Regulus Therapeutics Dominari Fortress Biotech Agenus Bolt Biotherapeutics SAB Biotherapeutics Molecular Templates Amgen Gilead Sciences Lexicon Pharmaceuticals (NASDAQ:LXRX) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability. Do analysts recommend LXRX or CRIS? Lexicon Pharmaceuticals currently has a consensus target price of $3.67, indicating a potential upside of 954.85%. Curis has a consensus target price of $23.00, indicating a potential upside of 854.36%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Curis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexicon Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Curis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, LXRX or CRIS? Lexicon Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.49, indicating that its share price is 249% more volatile than the S&P 500. Is LXRX or CRIS more profitable? Curis has a net margin of -443.35% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Lexicon Pharmaceuticals' return on equity of -107.38% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets Lexicon Pharmaceuticals-4,109.41% -107.38% -64.09% Curis -443.35%-923.37%-78.35% Does the MarketBeat Community favor LXRX or CRIS? Curis received 210 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 67.68% of users gave Curis an outperform vote while only 64.23% of users gave Lexicon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexicon PharmaceuticalsOutperform Votes48364.23% Underperform Votes26935.77% CurisOutperform Votes69367.68% Underperform Votes33132.32% Which has higher valuation and earnings, LXRX or CRIS? Curis has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexicon Pharmaceuticals$31.08M2.75-$177.12M-$0.64-0.54Curis$10.26M1.99-$47.41M-$7.81-0.31 Does the media favor LXRX or CRIS? In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than Curis. MarketBeat recorded 5 mentions for Lexicon Pharmaceuticals and 1 mentions for Curis. Curis' average media sentiment score of 0.94 beat Lexicon Pharmaceuticals' score of 0.57 indicating that Curis is being referred to more favorably in the news media. Company Overall Sentiment Lexicon Pharmaceuticals Positive Curis Positive Do institutionals & insiders have more ownership in LXRX or CRIS? 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryLexicon Pharmaceuticals and Curis tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.41M$3.04B$5.65B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-0.3129.2923.1619.03Price / Sales1.99436.17386.8193.17Price / CashN/A168.6838.1634.64Price / Book0.723.956.914.33Net Income-$47.41M-$71.95M$3.20B$247.06M7 Day Performance-9.40%-3.76%-2.30%-0.37%1 Month Performance-19.67%-10.33%2.86%-3.85%1 Year Performance-77.83%-27.15%10.51%1.27% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.5705 of 5 stars$2.41+0.8%$23.00+854.4%-77.8%$20.41M$10.26M-0.3160LXRXLexicon Pharmaceuticals3.5274 of 5 stars$0.38+4.9%$3.67+854.1%-84.1%$94.63M$31.08M-0.51140Analyst ForecastShort Interest ↓RGLSRegulus Therapeutics3.3749 of 5 stars$1.37-7.4%$12.75+830.7%-47.9%$89.74MN/A-1.2830Analyst UpgradeNews CoveragePositive NewsGap UpDOMHDominari2.1198 of 5 stars$4.90+4.0%N/A+109.2%$53.47M$12.59M-1.274Positive NewsFBIOFortress Biotech2.3685 of 5 stars$1.75+4.8%$15.67+795.2%-20.3%$48.31M$62.50M-0.57170AGENAgenus3.7389 of 5 stars$1.78-4.3%$8.75+391.6%-85.1%$41.76M$160.43M-0.16440BOLTBolt Biotherapeutics3.5052 of 5 stars$0.41-0.9%$3.50+753.5%-64.0%$15.70M$9.78M-0.2490Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap UpSABSSAB Biotherapeutics3.683 of 5 stars$1.62+0.6%$12.40+665.4%-63.5%$14.95M$2.24M0.00140MTEMMolecular Templates0.7511 of 5 stars$0.00-80.0%N/AN/A$1,000.00$23.48M0.00260Gap UpAMGNAmgen4.4709 of 5 stars$317.17+1.1%$314.04-1.0%+6.8%$170.39B$33.42B42.0128,000Positive NewsGILDGilead Sciences4.6093 of 5 stars$112.26+0.7%$104.52-6.9%+52.3%$139.80B$28.75B303.4118,000Analyst ForecastPositive News Remove Ads Related Companies and Tools Related Companies Lexicon Pharmaceuticals Competitors Regulus Therapeutics Competitors Dominari Competitors Fortress Biotech Competitors Agenus Competitors Bolt Biotherapeutics Competitors SAB Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Gilead Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
